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Maurocalcine (MCa) is a 33 amino acid residue pep-
tide toxin isolated from the scorpion Scorpio maurus
palmatus. MCa and mutated analogues were chemically
synthesized, and their interaction with the skeletal mus-
cle ryanodine receptor (RyR1) was studied on purified
RyR1, sarcoplasmic reticulum (SR) vesicles, and cul-
tured myotubes. MCa strongly potentiates [3H]ryanod-
ine binding on SR vesicles (7-fold at pCa 5) with an
apparent EC50 of 12 nM. MCa decreases the sensitivity of
[3H]ryanodine binding to inhibitory high Ca2 concen-
trations and increases it to the stimulatory low Ca2
concentrations. In the presence of MCa, purified RyR1
channels show long-lasting openings characterized by a
conductance equivalent to 60% of the full conductance.
This effect correlates with a global increase in Ca2
efflux as demonstrated by MCa effects on Ca2 release
from SR vesicles. In addition, we show for the first time
that external application of MCa to cultured myotubes
produces a cytosolic Ca2 increase due to Ca2 release
from 4-chloro-m-cresol-sensitive intracellular stores.
Using various MCa mutants, we identified a critical role
of Arg24 for MCa binding onto RyR1. All of the other MCa
mutants are still able to modify [3H]ryanodine binding
although with a decreased EC50 and a lower stimulation
efficacy. All of the active mutants produce both the ap-
pearance of a subconductance state and Ca2 release
from SR vesicles. Overall, these data identify some
amino acid residues of MCa that support the effect of
this toxin on ryanodine binding, RyR1 biophysical prop-
erties, and Ca2 release from SR.
In skeletal muscles, contraction is triggered by the massive
release of Ca2 from sarcoplasmic reticulum (SR).1 The chan-
nel responsible for this release is the type-1 ryanodine receptor
(RyR1). RyR1 has been intensively studied because of its
unique structural and functional organization. It forms part of
a calcium mobilization complex in which RyR1 is apposed to
the L-type voltage-dependent calcium channel (dihydropyridine
receptor, DHPR) along many other structural and regulatory
components (1). The activation of RyR1 requires a chain of
events that starts with plasma membrane depolarization in-
ducing a change in the conformation of DHPR itself transmit-
ted to RyR1. The entire set of events is called excitation-con-
traction coupling (EC coupling).
In vitro, the activity of RyR1 can be modulated by a number
of different effectors such as Ca2, ryanodine, ATP, caffeine,
and 4-chloro-m-cresol (CMC) (2, 3). Among these effectors, only
few present high selectivity and affinity for RyR1. More specific
pharmacological agents for RyR1 have been discovered in scor-
pion venoms (4, 5). One such peptide has been isolated from the
venom of the chactid scorpion Scorpio maurus palmatus and
has been termed maurocalcine (MCa). It is a 33-mer basic
peptide reticulated by three disulfide bridges. MCa can be
chemically synthesized without any loss of activity (5). It is
potently active on RyR1 as it alters channel properties in the
low nanomolar range (5, 6). MCa presents a strong sequence
homology (82% amino acid sequence identity) with imperatoxin
A (IpTxA), a toxin active on RyR1 and isolated from another
scorpion venom (7–10). Besides the fact that MCa and IpTxA
represent two of the most high affinity effectors of RyR1, they
also share some amino acid sequence homology with a specific
domain (domain A) of the II–III loop of Cav1.1, the subunit
that carries the voltage sensor of DHPR (Fig. 1). Although the
exact role of the domain A in the EC-coupling process is highly
debated (11–13), we have recently shown by using plasmon
resonance measurements that it is the single II–III loop se-
quence interacting with RyR1 (14). Nevertheless, this excep-
tional form of homology between a channel sequence and a
toxin could be indicative that domain A possesses some kind of
yet unresolved function in RyR1 regulation. Therefore, study-
ing the MCa effects on RyR1 may produce several interesting
hints on how to proceed further on investigating the role of
domain A in EC coupling.
In this work, we synthesized several MCa analogues in
which amino acid residues, also present in homologous position
in domain A, were substituted by alanine residues. We then
analyzed the effect of MCa and the analogues on [3H]ryanodine
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binding, Ca2-dependent activation of RyR1, channel activity,
and Ca2 release from SR vesicles. We identified an amino acid
residue critical for the interaction of MCa with RyR1 and for
the induction of a long-lasting subconductance state. The data
also demonstrate a clear relationship in the ability of MCa to
potentiate [3H]ryanodine binding, induce a subconductance
state, and produce Ca2 release from heavy SR vesicles. To
prove the physiological relevance of RyR1 as the main target of
MCa, we tested the effect of the peptide on internal Ca2
release in intact myotubes. We show that the addition of 100 nM
MCa in Ca2-free extracellular medium induces an increase in
cytosolic Ca2 concentration and a complete inhibition of CMC-
induced Ca2 release.
EXPERIMENTAL PROCEDURES
Chemical Synthesis—N--Fmoc-L-amino acids, 4-hydroxymethylphe-
nyloxy resin, and reagents used for peptide synthesis were obtained
from PerkinElmer Life Sciences. The MCa and analogues were obtained
by the solid-phase peptide synthesis (15) using an automated peptide
synthesizer (Model 433A, Applied Biosystems Inc.). Analogues were
obtained by point mutation (Ala instead of one amino acid in the
sequence of maurocalcine native-like) and named Ala/Lys8, Ala/Lys19,
Ala/Lys20, Ala/Lys22, Ala/Arg23, Ala/Arg24, and Ala/Thr26. Peptide
chains were assembled stepwise on 0.25 meq of hydroxymethylpheny-
loxy resin (1% cross-linked; 0.89 meq of amino group/g) using 1 mmol of
N--Fmoc amino acid derivatives. The side chain-protecting groups
were as follows: trityl for Cys and Asn; tert-butyl for Ser, Thr, Glu, and
Asp; pentamethylchroman for Arg; and tert-butyloxycarbonyl for Lys.
N--Amino groups were deprotected by treatment with 18 and 20% (v/v)
piperidine/N-methylpyrrolidone for 3 and 8 min, respectively. The
Fmoc-amino acid derivatives were coupled (20 min) as their hydroxy-
benzotriazole active esters in N-methylpyrrolidone (4-fold excess). After
peptide chain assembly, the peptide resin (approximately 1.8 g) was
treated between 2 and 3 h at room temperature in constant shaking
with a mixture of trifluoroacetic acid/H2O/thioanisol/ethanedithiol (88:
5/5/2, v/v) in the presence of crystalline phenol (2.25 g). The peptide
mixture was then filtered, and the filtrate was precipitated by adding
cold t-butylmethyl ether. The crude peptide was pelleted by centrifuga-
tion (3.000  g for 10 min), and the supernatant was discarded. The
reduced peptide was then dissolved in 200 mM Tris-HCl buffer, pH 8.3,
at a final concentration of 2.5 mM and stirred under air to allow
oxidation/folding (between 50 and 72 h, room temperature). The target
products, MCa and analogues, were purified to homogeneity, first by
reversed-phase high pressure liquid chromatography (PerkinElmer
Life Sciences, C18 Aquapore ODS, 20 m, 250  10 mm) by means of a
60-min linear gradient of 0.08% (v/v) trifluoroacetic acid  0–30%
acetonitrile in 0.1% (v/v) trifluoroacetic acid/H2O at a flow rate of 6
ml/min (  230 nm). A second step of purification of MCa and ana-
logues was achieved by ion-exchange chromatography on a carboxym-
ethyl cellulose matrix using 10 mM (buffer A) and 500 mM (buffer B)
sodium phosphate buffers, pH 9.0 (60-min linear gradient from 0 to 60%
buffer B at a flow rate of 1 ml/min). The homogeneity and identity of
MCa or analogues were assessed by the following: (i) analytical C18
reversed-phase high pressure liquid chromatography (Merck, C18 Li-
Chrospher, 5 m, 4  200 mm) using a 60-min linear gradient of 0.08%
(v/v) trifluoroacetic acid/0–60% acetonitrile in 0.1% (v/v) trifluoroacetic
acid/H2O at a flow rate of 1 ml/min; (ii) amino acid analysis after
acidolysis (6 N HCl/2% (w/v) phenol, 20 h, 118 °C, N2 atmosphere); and
(iii) mass determination by matrix-assisted laser desorption ionization
time-of-flight mass spectrometry.
Heavy SR Vesicles Preparation—Heavy SR vesicles were prepared
following a modified method of Kim et al. (16) as described in Marty et
al. (17). Protein concentration was measured by the Biuret method.
[3H]Ryanodine Binding Assay—Heavy SR vesicles (1 mg/ml) were
incubated at 37 °C for 2.5 h in an assay buffer composed of 5 nM
[3H]ryanodine (unless otherwise stated), 150 mM NaCl, 2 mM EGTA,
variable concentrations of CaCl2 to adjust for pCa, and 20 mM HEPES,
pH 7.4. MCa or peptide mutants were added to the assay buffer just
prior to the addition of heavy SR vesicles. [3H]Ryanodine bound to
heavy SR vesicles was measured by filtration through Whatmann GF/B
glass filters followed by three washes with 5 ml of ice-cold washing
buffer composed of 150 mM NaCl, 20 mM HEPES, pH 7.4. Filters were
then soaked overnight in 10 ml of scintillation mixture (Cybscint, ICN),
and bound radioactivity was determined by scintillation spectrometry.
Nonspecific binding was measured in the presence of 20 M cold ryan-
odine. Each experiment was performed in triplicate and repeated at
least twice. All of the data are presented as the mean  S.E.
Ca2 Release Measurements—Ca2 release from heavy SR vesicles
was measured using the Ca2-sensitive dye, antipyrylazo III. The ab-
sorbance was monitored at 710 nm by a diode array spectrophotometer
(MOS-200 Optical System, Biologic, Claix, France). Heavy SR vesicles
(50 g) were actively loaded with Ca2 at 37 °C in a 2-ml buffer con-
taining 100 mM KCl, 7.5 mM sodium pyrophosphate, 20 mM potassium
MOPS, pH 7.0, supplemented with 250 M antipyrylazo III, 1 mM
ATP/MgCl2, 5 mM phosphocreatine, and 12 g/ml creatine phospho-
kinase (18). Ca2 loading was started by sequential additions of 50 and
20 M of CaCl2. In these loading conditions, no calcium-induced calcium
release interferes with the observations. At the end of each experiment,
Ca2 remaining in the vesicles was determined by the addition of Ca2
ionophore A23187 (4 M) and the absorbance signal calibrated by two
consecutive additions of 20 M CaCl2.
RyR1 Ca2 Channel Reconstitution and Single-channel Recording
Analysis—Measurements of channel activity were carried out using
purified RyR1 incorporated into planar lipid bilayers. RyR1 was puri-
fied from rabbit SR vesicles as previously described (19). The bilayers
were formed using phosphatidylethanolamine, phosphatidylserine, and
L-phosphatidylcholine in a ratio of 5:4:1 dissolved in n-decane up to the
final lipid concentration of 20 mg/ml (20). Bilayers were formed across
a 200- or 250-m diameter aperture of a Delrin cap using a symmetrical
buffer solution (250 mM KCl, 100 M EGTA, 150 M CaCl2, 20 mM
PIPES, pH 7.2). The chamber into the small aliquot of purified RyR1
was added and defined as the cis (cytoplasmic) side, whereas the other
chamber labeled as the trans (luminal) side was kept on ground poten-
tial. To ensure the orientation of the incorporated RyR1, we tested the
effect of free Ca2 concentration on both side. After successful incorpo-
ration of the RyR1 channel, free calcium concentration in the cis cham-
ber was adjusted to 238 nM by the addition of EGTA. Electrical signals
were filtered at 1 kHz through an 8-pol low-pass Bessel filter and
digitized at 3 kHz using Axopatch 200 and pCLAMP 6.03 (Axon Instru-
ments, Union City, CA).
Total recording time in each experiment was 10–20 min for any
experimental condition tested. After changing conditions, at least 5 min
were allowed for equilibration, which appeared to be enough to reach
the new equilibrium of the parameters. Single channel measurements
were carried out at 20–22 °C. The free Ca2 concentration was calcu-
lated using the computer program and affinity constants published by
Fabiato (21). Open probabilities were calculated using the common 50%
criteria with a medial dead zone of 5%. Current amplitude distribution
was analyzed using Origin (Microcal Software, Northampton, MA).
Values of the open probability are expressed as the means  S.E.
Cell Culture—Primary cultures of rat skeletal muscle satellite cells
were obtained as described previously (16). Cells were seeded on lami-
nin-coated plates, in a proliferation medium composed of Ham’s F-10
with glutamax-I (Invitrogen) supplemented with 20% fetal calf serum
(Invitrogen), 2.5 ng/ml basic fibroblast growth factor (Invitrogen), and
1% penicillin-streptomycin (Invitrogen) at 37 °C and 5% CO2. After 2–3
days, differentiation of satellite cells into myotubes was induced with
Dulbecco’s modified Eagle’s medium with glutamax-I (Invitrogen) sup-
plemented with 10% horse serum (Invitrogen).
Ca2 Imaging from Culture Myotubes—Changes in cytosolic calcium
levels were monitored using the calcium-dependent fluorescent dye
Fluo-4 (Molecular Probes). The myotubes were loaded for 1 h at room
temperature in the presence of 5 M Fluo-4-AM. Uptake of the dye was
facilitated by the addition of 0.02% pluronic acid (Sigma). After loading,
myotubes were washed for 1 h to allow ester hydrolysis of the dye.
Fluorescence changes were measured by confocal laser-scanning mi-
croscopy using a LEICA TCS-SP2 operating system in the xyt mode.
Fluo4 was excited at a wavelength of 488 nm, and the fluorescence was
collected from 500 to 570 nm. Images were collected every 1.6 s for 2–4
min and then analyzed frame by frame with the data analysis software
provided by Leica. Fluorescence curves are expressed as a function of
time as F/F, where F represents the base-line fluorescence and F
represents the fluorescence variations.
RESULTS
Synthesis of MCa and Analogues—Fig. 1 presents the pri-
mary structure of the different MCa analogues that we synthe-
sized. The structural determination of MCa shows that the
stretch of basic residues (from Lys20 to Arg24) forms a single
basic-rich surface (22). We will define the residues forming this
basic surface as residues belonging to the “basic class.” The
opposite surface of the toxin contains four acidic residues (Asp2,
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Glu12, Asp15, and Glu29) and one basic residue (Lys8). We will
define this acidic surface as the “acidic face.” This electrostatic
charge distribution creates a marked anisotropy in which the
role in MCa pharmacology is unknown. We choose to substitute
one by one all of the MCa amino acid residues common between
MCa and the domain A of the II–III loop of Cav1.1 subunit.
Most of these residues belong to the basic class with the excep-
tion of Thr26 and therefore were replaced by neutral alanine
residues. We also synthesized the mutant [Ala8]MCa because
Lys8 is not conserved in the II–III loop but is located on the
toxin face opposite to the basic surface (23). All of the peptides
were folded/oxidized in a 200 mM Tris-HCl buffer, pH 8.3, by a
72-h exposure to air and purified to homogeneity by prepara-
tive C18 reversed-phase high pressure liquid chromatography.
Both analysis of elution profiles and circular dichroism spectra
indicate that all of the peptides have proper secondary struc-
tures (data not shown).
Effects of MCa on [3H]Ryanodine Binding to RyR1—We re-
cently described that MCa stimulates the binding of [3H]ryano-
dine onto heavy SR vesicles that contain RyR1 (6). Fig. 2A
confirms this initial finding as we observe that 200 nM MCa
increases the binding of [3H]ryanodine by 7.4 2.5-fold with an
EC50 of 12.5  0.8 nM. Results presented in Fig. 2B show that
MCa induces a slight change in the [3H]ryanodine binding
kobsvalue (kobs  1.08  10
2  0.22  102 min1 without
MCa versus kobs  1.81  10
2  0.23  102 min1 with 100
nM MCa). As shown in Fig. 2C, [3H]ryanodine binding on RyR
highlights both a high affinity (51 nM) and a low affinity (228
nM) class of binding sites, whereas in the presence of MCa (100
nM), ryanodine binding on RyR1 exhibits a single class of high
affinity binding site (11 nM). These results suggest that the
increase of ryanodine binding induced by MCa may be because
of a conversion of both classes of binding sites into a higher
affinity class of binding site. Because [3H]ryanodine binding on
SR vesicles is sensitive to external Ca2 concentration, we
examined the effect of MCa on [3H]ryanodine binding in the
presence of varying external Ca2 concentrations (Fig. 2D). In
the presence of MCa (saturating 100 nM), [3H]ryanodine bind-
ing on SR vesicles still shows a classical bell-shaped depend-
ence to external Ca2. Interestingly, we observed that the
[3H]ryanodine binding inhibition by high Ca2 concentration
(pCa 3) was slightly decreased, whereas the [3H]ryanodine
binding stimulation by low Ca2 concentration (pCa 6 and 6.5)
was increased. Indeed, while in the absence of MCa, ryanodine
binding was almost completely inhibited (99%) at pCa 3. In
the presence of MCa, 39% of the maximum [3H]ryanodine bind-
ing was still observed at pCa 3. Similarly, at pCa 6.5, ryanodine
binding is at 70% of its maximum in the presence of MCa,
whereas it is only at 4.8% of its maximum in the absence
of MCa.
Characterization of the Effects of MCa Mutants on [3H]Ry-
anodine Binding to RyR1—All of the MCa analogues also stim-
ulate [3H]ryanodine binding (Fig. 3A) with the exception of
[Ala24]MCa (up to 5 M). For all of the functional analogues, the
EC50 of the stimulatory effect is reduced with values ranging
between 49  14 nM for [Ala26]MCa and 432  168 nM for
[Ala22]MCa, which would correspond to a reduction of affinity
between 4- and 35-fold. [Ala8]MCa also appeared less effective
than MCa with an EC50 of 199  19 nM. These data show that
the amino acid residues of MCa can be classified in three
different groups: (i) residues belonging to the basic class that
are important for interaction with RyR1 (Lys22, Arg23, and
Arg24); (ii) residues belonging or not to the basic class that
appear less important for the interaction with RyR1 (Lys19,
Lys20, and Thr26); and (iii) a residue of the acidic face that
appears to mildly affect the interaction with RyR1 (Lys8). Be-
sides various effects on EC50, all of the active analogues also
present a significant decrease on the stimulation efficacy on
[3H]ryanodine binding. The stimulation efficacies of the ana-
logues are on average 1.9-fold less than MCa itself and ranged
between 3.2  0.4-fold for [Ala23]MCa and 4.7  0.1-fold for
[Ala8]MCa. [Ala23]MCa combines two negative changes com-
FIG. 1. Sequence alignment of domain A, IpTxA, MCa, and MCa analogues. Schematic representation of the DHPR complex illustrating
the subunit composition. MCa has sequence similarities with domain A of the II–III loop from the Cav1.1 subunit of DHPR and with IpTxA,
another scorpion toxin. The homology stretches from Lys19 to Thr26 of MCa. The primary structure of the mutated MCa analogues is also shown.
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pared with wild-type MCa, a decrease in the apparent affinity
and the lowest [3H]ryanodine binding stimulation efficacy. Two
explanations can be put forward to explain why [Ala24]MCa is
ineffective on [3H]ryanodine binding. Firstly, it may not bind to
RyR1, which is the simplest hypothesis. Secondly, it may bind
onto RyR1 but cannot produce allosteric changes required to
enhance [3H]ryanodine binding. In this latest case, [Ala24]MCa
would compete with MCa for binding on RyR1. To test this
hypothesis, we measured the effect of MCa (20 and 100 nM) on
[3H]ryanodine binding in the presence of increasing concentra-
tions of [Ala24]MCa. Fig. 3B shows that the effect of MCa is not
altered by the presence of up to 1 M [Ala24]MCa, demonstrat-
ing that this analogue is not able to bind onto RyR1. We also
checked whether or not the absence of the effect of [Ala24]MCa
on [3H]ryanodine binding is related to experimental pCa con-
ditions. Indeed, no [3H]ryanodine binding stimulation was ob-
served at pCa values ranging between 2 and 7 (Fig. 3C).
Characterization of the Effects of MCa and MCa Mutants on
Ca2 Release from SR Vesicles—To investigate the effect of
MCa on Ca2 release from heavy SR vesicles, we first actively
loaded the vesicles by two consecutive additions of Ca2 (50 M
and 20 M) in the presence of ATP-Mg2, pyrophosphate, and
ATP-regenerating system. After Ca2 loading reaches equilib-
rium, the addition of 1 M MCa to the external medium induces
Ca2 release as shown in Fig. 4A. Similar results were obtained
with 100 nM MCa (data not shown), but 1 M MCa was chosen
to allow a comparison with the effects of the lower affinity MCa
analogues. External Ca2 level reaches a plateau that corre-
sponds to a new equilibrium between Ca2 release and Ca2
uptake rates as evidenced by the additional change produced
by 4 M A23187 calcium ionophore. The release of Ca2 induced
by 1 M MCa was prevented by preincubating the SR vesicles
with 10 M ruthenium red, demonstrating that MCa-induced
calcium release occurs through RyR (Fig. 4B). Similarly, the
application of 1 M MCa prevents the release of Ca2 induced
by the addition of 500 M CMC, and conversely, the application
of 500 M CMC prevents an additional release of Ca2 by 1 M
MCa (Fig. 4C). These data again demonstrate that MCa re-
FIG. 2. MCa affects [3H]ryanodine binding on heavy SR vesicles. A, MCa concentration dependence of [3H]ryanodine binding stimulation.
[3H]Ryanodine binding was measured at pCa 5 in the presence of 5 nM [3H]ryanodine for 2.5 h at 37 °C. Nonspecific binding remained constant
at all of the MCa concentrations and represented 8% of total binding. Data were fitted with a sigmoid function y  yo  (a  x
b/cb  xb), where
yo  1.0  0.1 at MCa  0 nM, a  6.7  0.2 is the maximum stimulation factor over basal value, b  1.3  0.1 the slope coefficient, and c  12.5 
0.8 nM is the EC50 for MCa effect. B, kinetics of [
3H]ryanodine binding in the absence (filled circles) and presence of 100 nM MCa (open circles). Data
were fitted with an exponential curve y  a  (1  exp(kt)) with a being the maximal achievable normalized binding and k being the pseudo first
order rate constant (kobs) value for [
3H]ryanodine binding. a  0.99  0.01 and kobs  1.08  10
2  0.22  102 min1 (without MCa), and a 
0.94  0.01 and kobs  1.81  10
2  0.23  102 min1 (with 100 nM MCa). C, Scatchard representation of the concentration-dependent
[3H]ryanodine binding in the absence (filled circles) and presence of 100 nM MCa (open circles). Experimental conditions in B and C were as
described in A. D, extravesicular Ca2 concentration dependence of [3H]ryanodine binding in the absence (filled circles) and presence of 100 nM
MCa (open circles). The experiments were performed with 5 nM [3H]ryanodine for 2.5 h at 37 °C.
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leases Ca2 from SR vesicles by acting on RyR. Fig. 4D shows
that the application of 1 M of any one of the mutated MCa
analogues induces Ca2 release from SR vesicles with the
exception of [Ala23]MCa and [Ala24]MCa. However, these two
last MCa analogues are not equivalent since application of 10
M [Ala23]MCa resulted in Ca2 release, whereas 10 M
[Ala24]MCa remained inactive (Fig. 4E). The present observa-
tion made for [Ala24]MCa is in complete agreement with its
lack of effect on [3H]ryanodine binding (Fig. 3B). The results
obtained with [Ala23]MCa are also coherent with the data on
[3H]ryanodine binding (lower affinity and lower stimulation
efficacy), although a discrepancy exists between the
[Ala23]MCa concentration needed for Ca2 release and those
inducing an increase in [3H]ryanodine binding.
Modification of RyR1 Calcium Channel Conductance by MCa
and Analogues—Application of 200 nM MCa to the cis face of
the bilayer-recording chamber (cytoplasmic side of RyR1) in-
duces a characteristic long-lasting subconductance state
(LLSS) (Fig. 5A). This subconductance state represents 60% of
the full conductance state, and the channel spends 54.8  6.2%
of its time in this subconductance level. A much less frequent
smaller LLSS (48% of the full conductance) was described in
earlier reports (5, 6), but the experimental conditions were
slightly different (purified RyR1 versus junctional SR vesicles
and K current versus Cs current in previous reports (5, 6)).
We next examined whether the LLSS induced by MCa could be
correlated to Ca2 release from heavy SR vesicles and stimu-
lation of [3H]ryanodine binding. Therefore, we tested the effect
of [Ala24]MCa on the conductance level of RyR1 in lipid bilayers
(Fig. 5B). Indeed, this mutant peptide has no effect on [3H]ry-
anodine binding (Fig. 3A) nor on the Ca2 release from SR
vesicles (Fig. 4D). As expected, we show that the application of
200 nM [Ala24]MCa does not induce any LLSS of RyR1. Appli-
cations of higher concentrations (up to 750 nM) also were with-
out any effect (data not shown). Conversely, the application of
200 nM of an active MCa analogue, [Ala20]MCa, that conserves
MCa-like properties (for [3H]ryanodine binding and Ca2 re-
lease from SR vesicles) produces the appearance of the charac-
FIG. 3. Effect of MCa analogues on [3H]ryanodine binding to heavy SR vesicles. A, [3H]ryanodine binding was measured as described
in Fig. 2A in the presence of various concentrations of each MCa analogue (open circles). For comparison, the solid line represents the fit of the data
shown in Fig. 2A for MCa. The EC50 values for each analogue were calculated as in Fig. 2A and reported in insert. B, effect of varying [Ala
24]MCa
concentration on [3H]ryanodine binding measured in the absence (filled circles) and presence of 20 (gray circles) and 100 nM MCa (open circles).
C, extravesicular Ca2 concentration dependence of [3H]ryanodine binding in the absence (filled triangles) and presence of 300 nM [Ala24]MCa (gray
triangles). The experiments were performed with 5 nM [3H]ryanodine for 2.5 h at 37 °C.
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FIG. 4. Ca2 release from heavy SR vesicles induced by MCa and MCa analogues. A, heavy SR vesicles were actively loaded with Ca2
by sequential addition of 50 and 20 M CaCl2 in the monitoring chamber. After each increment, the absorbance was monitored until the added Ca
2
was taken up by SR and the trace relaxed close to its original base line (CaCl2 additions constituting 	70–80% of their loading capacity). In these
conditions, the addition of 1 M MCa produces Ca2 release. The addition of 4 M A23187 empties the SR vesicles (open arrow). Calibration of Ca2
release is performed by two consecutive additions of 20 M Ca2 (data not shown). B, similar experiment as in A but with a preliminary application
of 10 M ruthenium red (RR). RR produces a deflection of absorbance due to its optical properties. C, traces illustrating the lack of effect of 500
M CMC after MCa application (left) and, conversely, the lack of effect of 1 M MCa after application of 500 M CMC (right). D, similar experiments
as in A but with 1 M of various MCa analogues. Two consecutive applications were performed for [Ala23]MCa. E, traces illustrating the
maintenance of effect of MCa on Ca2 release despite the prior application of [Ala23]MCa (left) or [Ala24]MCa (right).
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FIG. 5. MCa but not [Ala24]MCA induces long-lasting openings of RyR1. Single channel recordings were taken as described under “Experimental
Procedures.” The holding potential was80 mV, the conductance of the RyR was approximately 500 pS. The time duration of each record is 20 s. Channel
openings are downward deflections, and C and O designate the closed and opened state of the channel, respectively. Each toxin was applied at a
concentration of 200 nM in the cis chamber. Free Ca2 concentration was 238 nM in the cis chamber. A, control and MCa-induced RyR1 channel activity. Left
panel, representative current traces. Right panel, current amplitude histograms. B, as in A but for [Ala24]MCa. C, as in A but for [Ala20]MCa.
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teristic LLSS. With this analogue, the LLSS are characterized
by a conductance corresponding to 54% of the full-conductance
state. Under this condition, the channel spends on average
28  8.6% of its time in this state (data not shown). The lesser
probability for RyR1 to develop in the LLSS in the presence of
[Ala20]MCa compared with MCa may be related to a lesser
ability to stimulate [3H]ryanodine binding (Fig. 3A). Other
analogues including [Ala23]MCa also produced LLSS (data
not shown).
Intracellular Ca2 Release in Intact Myotubes Induced by
MCa—We next analyzed the effect of MCa on cytosolic Ca2
variations by changes in Fluo-4 fluorescence levels in cultured
myotubes. Extracellular application of 100 nM MCa on a group
of representative myotubes produces a fast increase in intra-
cellular Ca2 level (Fig. 6A). The time course of the change in
fluorescence level (F/F) shows that Ca2 increase occurs
within 3 s followed by a rapid decrease back to the basal level
(Fig. 6B). MCa produces a similar elevation in cytosolic Ca2
when extracellular medium is supplemented with 50 M La3
and deprived of Ca2 by the addition of 1 mM EGTA (Fig. 6B).
This observation demonstrates that MCa-induced Ca2 mobi-
lization occurs from internal sources. An analysis of the aver-
age change in fluorescence level confirms that there is no
significant difference in cytosolic Ca2 elevation in the absence
or presence of extracellular Ca2 (Fig. 6C). In similar experi-
mental conditions, external application of 250 M CMC also
induces a rapid and transient Ca2 elevation (Fig. 6D) (24). A
prior incubation of the myotube with 100 nM MCa almost
totally prevents CMC-induced peak Ca2 elevation (Fig. 6D).
This observation was confirmed by an average quantification of
fluorescence variation (mean F/F  79  67 (n  53) for CMC
alone versus 4  7 (n  91) for CMC after MCa) (Fig. 6E). We
also analyzed the cell variability in response to CMC alone or
CMC after MCa application (Fig. 6F). In the presence of CMC,
most myotubes (85.6%) produce important changes in fluores-
cence (F/F  50%), whereas after incubation with MCa, an
opposite profile of responses is observed with 47% of the cells
showing 10% change in fluorescence (F/F  0–10%). These
results demonstrate that the CMC-sensitive Ca2 stores are
also MCa-sensitive. Because CMC is known to act on intracel-
lular Ca2 stores by the bias of RyR (2), this is another indi-
cation that MCa acts on RyR-dependent Ca2 stores. To con-
firm that the effect of MCa on Ca2 elevation is the result of an
interaction with RyR, we also tested the effect of the mutant
[Ala24]MCa. We show that it is unable (i) to produce a Ca2
release from myotubes (Fig. 7A) and (ii) to modify CMC effect
(Fig. 7B).
DISCUSSION
In skeletal muscles, RyR1 appears to represent the main
target of MCa. We have previously shown that this toxin stim-
ulates [3H]ryanodine binding, stabilizes RyR1 into a subcon-
ductance state, and produces Ca2 release from heavy SR
vesicles. In this work, we further investigated the biochemical
and functional properties of MCa. Using synthetic mutated
analogues of MCa, we defined some critical amino acid residues
of MCa that are required for its effects on RyR1. We also show
for the first time that MCa is able to induce intracellular Ca2
release in intact myotubes. This effect is conserved in the
absence of external Ca2, demonstrating that the increase in
FIG. 6. MCa induces a cytosolic Ca2 transient in cultured myotubes. A, confocal images of myotubes after 3 days in culture. Left,
transmitted light image (differential interference contrast). Right and bottom, Fluo-4 fluorescence images acquired before (control) and at indicated
times after application of 100 nM MCa. B, MCa-induced fluorescence variations of Fluo-4-loaded myotubes measured in the absence () and
presence () of extracellular Ca2. C, mean peak value of Fluo-4 fluorescence variation induced by 100 nM MCa with or without extracellular Ca2.
D, fluorescence variation induced by 250 M CMC without (black line) or with (gray line) a preapplication of 100 nM MCa. E, mean peak value of
fluorescence variations induced by CMC without or with preapplication of 100 nM MCa. F, percent of myotubes as a function of the peak value of
the fluorescence change induced by CMC without or with preapplication of MCa.
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cytoplasmic Ca2 concentration is due to the release of Ca2
from internal stores. In these conditions, Ca2 release induced
by CMC, a RyR1 agonist, is completely inhibited by the preap-
plication of MCa. Conversely, the application of the inactive
[Ala24]MCa analogue does not induce any Ca2 release from
internal stores nor does it inhibit CMC-induced Ca2 release.
These data demonstrate that Ca2 release induced by MCa
occurs through RyR1 activation. The cellular effect of MCa is of
the greatest importance because it demonstrates that the toxic
effect of the toxin can be explained by its action on RyR1
despite the intracellular location of this target. This result also
reveals that MCa has the ability to cross the plasma membrane
of skeletal muscle cells, a property that is shared by some other
basic peptides (25). Cell penetration is expected to occur rapidly
as Ca2 elevation can be observed a few seconds after external
application of MCa.
We have identified Arg24 as a crucial amino acid residue for
the effects of MCa. Indeed, the replacement of Arg24 by an
alanine induces a complete loss of MCa effects on [3H]ryano-
dine binding, on the appearance of subconductance events, on
Ca2 release from SR vesicles, and on intact myotubes. Con-
versely, mutated analogues that appeared less crucial for RyR1
recognition all kept similar profiles of effects than did MCa.
Our data demonstrate that the loss of effects of [Ala24]MCa is
because of the inability of this analogue to bind onto RyR1.
Indeed, we show the absence of [Ala24]MCa effect on MCa-
induced stimulation of [3H]ryanodine binding and on MCa-
induced Ca2 release from SR vesicles. MCa and other func-
tional analogues, such as [Ala20]MCa, have in common the
ability to induce long-lived subconductance states of RyR1. The
appearance of this subconductance state probably explains the
release of Ca2 from SR vesicles and in part the stimulation of
[3H]ryanodine binding. This finding is coherent with the hy-
pothesis that ryanodine preferentially binds onto the open
state of RyR1 (26). There are interesting functional similarities
between ryanodine and MCa. Both appear able to induce sub-
conductance states, and MCa favors [3H]ryanodine binding.
These data strongly suggest the existence of a positive synergy
between the binding sites of the two molecules on RyR1. This
synergy is further evidenced by the fact that MCa increases by
a factor of 6.1-fold the affinity of [3H]ryanodine for RyR1. In
addition, in the presence of MCa, we observed a shift to lower
Ca2 concentrations of the Ca2 stimulatory effect on [3H]ry-
anodine binding and a shift to higher Ca2 concentrations of
the Ca2 inhibitory effect on [3H]ryanodine binding. These
data are in favor of a model in which the binding of either one
of these two molecules, ryanodine or MCa, produces a chain of
conformational events, leading to the appearance of subconduc-
tance states. All of the active MCa analogues that we tested
stimulated [3H]ryanodine binding with higher EC50 values
than MCa itself. We also measured a reduced ability to stimu-
late [3H]ryanodine binding. Although the substituted amino
acid residues of MCa do not appear decisive for the interaction
with RyR1, they seem to contribute to some extent to the
binding site recognition. In addition, they also appear to par-
ticipate to the conformational events that lead to the modifica-
tion of the low affinity ryanodine binding sites. We would
expect that more drastic substitutions within MCa lead to
modifications in the level of RyR1 subconductance states
and/or in the time spent in these subconductance states. In-
deed, it has been observed that IpTxA, which shares 82%
sequence identity with MCa, induces a subconductance state of
RyR significantly different from the one triggered by MCa (25%
of the full-conductance state for IpTxA versus 58% for MCa) (9,
10). Moreover, in contrast to what is observed with IpTxA,
LLSS induced by MCa and its analogues are polarity-inde-
pendent. Similarly, the domain A of the 1 subunit of DHPR
that shares sequence similarities with both MCa and IpTxA
also induces a subconductance state different from those ob-
served with the toxin (65 and 86% of the full-conductance state
for domain A) (6). Based on sequence identity, it is probable
that MCa and IpTxA bind more than one common site(s) or
regions on the RyR1 tetramer. Interestingly, the binding of two
structurally related molecules on the same channel can pro-
duce highly different conductance states of RyR1. Therefore, it
is tempting to postulate that once MCa or IpTxA is bound on
RyR1, structural modification of these ligands could produce
important changes in the conductance properties of RyR1. This
concept of RyR1 conductance modulation could be applied to
domain A to provide an explanation for its role in the regula-
tion of RyR1 function. Recently, it was proposed that the three-
dimensional structural surface of MCa and IpTxA mimics that
of domain A (23). It would be interesting to investigate whether
conformational changes in domain A during membrane depo-
larization are of nature to modify RyR1 channel conductance.
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